[Relationship between vitamin D deficiency and metabolic syndrome in adult population of the Community of Madrid].
OBJECTIVE
Previous studies have suggested an association between MS and vitamin D deficiency, but data are not conclusive. This study was intended to find out if metabolic syndrome, according to the 2009 IDF/AHA/NHLBI, is associated to the presence of vitamin D deficiency.


METHODS
A cross-sectional study was conducted on a sample of 326 subjects aged 18 years or older, recruited from a health center in Alcalá de Henares. Participants underwent an interview and a standardized clinical examination. In a second visit, blood tests were performed in 255 subjects to quantify serum levels of 25-hydroxyvitamin D (25 OH-VitD) and different laboratory parameters associated to MS. The association between vitamin D deficiency and metabolic syndrome (and each of its components) was examined.


RESULTS
In the study population, MS prevalence was 36.1% and prevalence of vitamin D deficiency (25 OH-Vit D<20 ng/mL) was 56.3%. MS was more common in the group of patients with vitamin D deficiency (43.4%) than in the group with no deficiency (26.8%, P=.006), with an estimated prevalence ratio of 1.62 (95% CI: 1.13-2.31). Adjustment for age, sex, and body mass index did not change such association.


CONCLUSIONS
There is a significant association between vitamin D deficiency and MS. Both conditions are highly prevalent in our population.
Medicina de Familia y Comunitaria, Centro de Salud Luis Vives , Alcalá de Henares, España. Electronic address: antoniogradillas@yahoo.es.
Antonio
A
Gradillas-García
Departamento de Endocrinología y Nutrición, Hospital Universitario Príncipe de Asturias , Alcalá de Henares, España; Departamento de Medicina y Especialidades Médicas, Universidad de Alcalá, Alcalá de Henares, España.
Julia
J
Álvarez
Departamento de Endocrinología y Nutrición, Hospital Universitario Príncipe de Asturias , Alcalá de Henares, España; Departamento de Ciencias Biomédicas, Universidad de Alcalá, Alcalá de Henares, España.
José Antonio
JA
Rubio
Departamento de Ciencias Biomédicas, Universidad de Alcalá, Alcalá de Henares, España; Unidad de Farmacología Clínica, Hospital Universitario Príncipe de Asturias, , Alcalá de Henares, España.
Francisco J
FJ
de Abajo
D000328:Adult; D000368:Aged; D000886:Anthropometry; D001786:Blood Glucose / Q000032:analysis; D003430:Cross-Sectional Studies; D004032:Diet; D004198:Disease Susceptibility; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000453:epidemiology*; D008875:Middle Aged; D015995:Prevalence; D013030:Spain / Q000453:epidemiology; D014527:Uric Acid / Q000097:blood; D014807:Vitamin D / Q000031:analogs & derivatives / Q000097:blood; D014808:Vitamin D Deficiency / Q000097:blood / Q000453:epidemiology*
D001786:Blood Glucose; D006442:Glycated Hemoglobin; D008055:Lipids; D014527:Uric Acid; D014807:Vitamin D; C104450:25-hydroxyvitamin D
Diabetes tipo 2; Metabolic syndrome; Síndrome metabólico; Type 2 diabetes; Vitamin D; Vitamina D